Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine

Abstract Ovarian cancer has a poor cure rate and rates of relapse are high. Current recurrence detection is limited by non-specific methods such as blood testing and ultrasound. Based on reports that human epididymis four (HE4) / creatinine (CRE) ratios found in urine are elevated in ovarian cancers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emily C. Kight, Iftak Hussain, Audrey K. Bowden, Frederick R. Haselton
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a73edc14b2374ee8aa07670b68bbbf70
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a73edc14b2374ee8aa07670b68bbbf70
record_format	dspace
spelling	oai:doaj.org-article:a73edc14b2374ee8aa07670b68bbbf702021-11-14T12:21:19ZRecurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine10.1038/s41598-021-01544-42045-2322https://doaj.org/article/a73edc14b2374ee8aa07670b68bbbf702021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01544-4https://doaj.org/toc/2045-2322Abstract Ovarian cancer has a poor cure rate and rates of relapse are high. Current recurrence detection is limited by non-specific methods such as blood testing and ultrasound. Based on reports that human epididymis four (HE4) / creatinine (CRE) ratios found in urine are elevated in ovarian cancers, we have developed a paper-based device that combines lateral flow technology and cell phone analysis to quantitatively measure HE4/CRE. Surrogate samples were used to test the performance over clinically expected HE4/CRE ratios. For HE4/CRE ratios of 2 to 47, the percent error was found to be 16.0% on average whether measured by a flatbed scanner or cell phone. There was not a significant difference between the results from the cell phone or scanner. Based on published studies, error in this method was less than the difference required to detect recurrence. This promising new tool, with further development, could be used at home or in low-resource settings to provide timely detection of ovarian cancer recurrence.Emily C. KightIftak HussainAudrey K. BowdenFrederick R. HaseltonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Emily C. Kight Iftak Hussain Audrey K. Bowden Frederick R. Haselton Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
description	Abstract Ovarian cancer has a poor cure rate and rates of relapse are high. Current recurrence detection is limited by non-specific methods such as blood testing and ultrasound. Based on reports that human epididymis four (HE4) / creatinine (CRE) ratios found in urine are elevated in ovarian cancers, we have developed a paper-based device that combines lateral flow technology and cell phone analysis to quantitatively measure HE4/CRE. Surrogate samples were used to test the performance over clinically expected HE4/CRE ratios. For HE4/CRE ratios of 2 to 47, the percent error was found to be 16.0% on average whether measured by a flatbed scanner or cell phone. There was not a significant difference between the results from the cell phone or scanner. Based on published studies, error in this method was less than the difference required to detect recurrence. This promising new tool, with further development, could be used at home or in low-resource settings to provide timely detection of ovarian cancer recurrence.
format	article
author	Emily C. Kight Iftak Hussain Audrey K. Bowden Frederick R. Haselton
author_facet	Emily C. Kight Iftak Hussain Audrey K. Bowden Frederick R. Haselton
author_sort	Emily C. Kight
title	Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
title_short	Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
title_full	Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
title_fullStr	Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
title_full_unstemmed	Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine
title_sort	recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker he4/cre ratio in urine
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a73edc14b2374ee8aa07670b68bbbf70
work_keys_str_mv	AT emilyckight recurrencemonitoringforovariancancerusingacellphoneintegratedpaperdevicetomeasuretheovariancancerbiomarkerhe4creratioinurine AT iftakhussain recurrencemonitoringforovariancancerusingacellphoneintegratedpaperdevicetomeasuretheovariancancerbiomarkerhe4creratioinurine AT audreykbowden recurrencemonitoringforovariancancerusingacellphoneintegratedpaperdevicetomeasuretheovariancancerbiomarkerhe4creratioinurine AT frederickrhaselton recurrencemonitoringforovariancancerusingacellphoneintegratedpaperdevicetomeasuretheovariancancerbiomarkerhe4creratioinurine
_version_	1718429248118587392

Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine

Ejemplares similares